Back to search

Article

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkers

2023-12-02

Abstract excerpt

Advanced pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Immunotherapy alone offers limited efficacy, but its combination with chemotherapy could offer synergist anti-tumor effects. This phase Ib/II study evaluated the safety and efficacy of combining toripalimab with the albumin-paclitaxel plus gemcitabine (AG) regimen as first-line treatment for locally advanced or metastatic PDAC. The primary en...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f089d0c5-afa8-57f7-ab07-e24808507711
DOI
10.21203/rs.3.rs-3677396/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersDOI 10.21203/rs.3.rs-3677396/v1
Immunotherapy Combined with Chemotherapy versus Chemotherapy Alone in Advanced Pancreatic Ductal Adenocarcinoma: a Real-world Retrospective Cohort StudySemantic proximity
Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report.Semantic proximity
PD-1 blockade plus capecitabine as curative-intent treatment for tumor mutational burden-high multi-metastatic pancreatic ductal adenocarcinoma: A case reportSemantic proximity
Pancreatic biomarkers: could they be the answer?Semantic proximity
Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity
New therapeutic targets in pancreatic cancer.Semantic proximity
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.Semantic proximity
Current and future therapies for advanced pancreatic cancer.Semantic proximity
Exploring prognostic survival factors in patients with advanced pancreatic cancer receiving PD-1 inhibitorsSemantic proximity
Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.Semantic proximity
Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal AdenocarcinomaSemantic proximity
Select a neighboring publication to make it the new centre.